HWAM
DCPH

Hennion & Walsh Asset Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Hennion & Walsh Asset Management’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-33,942
Closed -$432K – 884
2023
Q3 		$432K Sell
33,942
-6,701
-16% -$92.4K 0.03% 559
2023
Q2 		$572K Sell
40,643
-26,881
-40% -$385K 0.03% 479
2023
Q1 		$1.04M Sell
67,524
-1,881
-3% -$31.4K 0.06% 347
2022
Q4 		$1.14M Sell
69,405
-30,128
-30% -$490K 0.07% 317
2022
Q3 		$1.84M Sell
99,533
-3,702
-4% -$58.1K 0.12% 205
2022
Q2 		$1.36M Buy
103,235
+1,592
+2% +$17.6K 0.08% 257
2022
Q1 		$942K Buy
101,643
+13,015
+15% +$111K 0.05% 360
2021
Q4 		$866K Buy
88,628
+19,087
+27% +$359K 0.04% 405
2021
Q3 		$2.36M Buy
69,541
+6,964
+11% +$222K 0.12% 221
2021
Q2 		$2.29M Buy
62,577
+21,854
+54% +$846K 0.12% 223
2021
Q1 		$1.83M Buy
+40,723
New +$1.9M 0.11% 248

Other funds holding DCPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hennion & Walsh Asset Management's DCPH Position: Q4 2023 in Review

Hennion & Walsh Asset Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2023, closing a stake of 33,942 shares — an estimated $432K sold.

Hennion & Walsh Asset Management first reported a position in DCPH in Q1 2021 and held it in 11 quarters. The position peaked at $2.36M in Q3 2021. 164 funds tracked by Wall St. Rank hold DCPH as of Q4 2023.

  • Hennion & Walsh Asset Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 33,942 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $432K.
  • Hennion & Walsh Asset Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Hennion & Walsh Asset Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $2.36M in Q3 2021.
  • 164 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2023, filed 10 Jan 2024.